Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07027683
Enrolling by invitation Observational

Cardiac Magnetic Resonance for Diagnosing and Guiding Treatment in Concealed Myocardial Rupture

NCT07027683 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Pisa
Phase
Observational
Started
2024-02-01
Last updated
2025-06-18

Condition(s) studied

Early Infarct-associated Pericarditis

Investigational drug(s) / intervention(s)

Cardiac MRI

Cardiac MRI: Post-MI cardiac MRI

Study summary

looking for the incidence of concealed myocardial rupture in patients with post infarct pericarditis

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * STEMI * Clinical diagnosis of Early infarct-associated pericarditis Exclusion Criteria: * None

Primary outcome measure(s)

  • Incidence of Myocardial rupture — 12 months

Trial sites (1)

FacilityCityRegionStatus
Università di Pisa Pisa Italy

More University of Pisa trials in Italy

Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients Recruiting
Clinical Outcomes of Immediate Implants With or Without a Volume-stable Collagen Matrix Active, not recruiting
Application of Ultra-high Frequency Ultrasonography (UHFUS) to the Study of Gingival Tissues Recruiting
Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients Recruiting
Evaluation of a Multimodal Tactile Feedback System for Upper Limb-loss Users: Embodiment and Performance Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07027683 on ClinicalTrials.gov ↗ ← All trials in Italy